Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017)

Harvard Bioscience (HBIO) reported Liabilities from Discontinued Operations of 1311000.0 for Q4 2017.

Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017) Analysis & Trends

Harvard Bioscience (HBIO) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 1311000.0 in Q4 2017.

Liabilities from Discontinued Operations for Q4 2017 came in at 1311000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was 1311000.0 (changed N/A YoY), and the FY2017 annual result was 1311000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations was little changed at 1311000.0 in Q4 2017 per HBIO's latest filing.
Over five years, Liabilities from Discontinued Operations peaked at 1311000.0 in Q4 2017 and troughed at 1311000.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn
10	Harvard Bioscience	26.17 Mn	19.07 Mn	12.24 Mn

Download Data

Date	Value
Dec 31, 2017	1.31 Mn
Dec 31, 2017	1.31 Mn